Alex Lu is an associate in the litigation department of Goodwin and a member of its Intellectual Property group. Ms. Lu focuses her practice on patent matters and has litigated patent infringement suits in the areas of biotechnology, pharmaceuticals, and network technology. Ms. Lu focuses a significant portion of her practice on legal and regulatory issues that arise in the emerging area of biosimilars. She is a regular contributor and editor of the Big Molecule Watch, an award-winning blog that reports real-time analysis and updates on regulatory issues, litigation, legislation and other news in the developing world of biosimilars (or “big molecules”). Ms. Lu is also a contributing author of Goodwin’s biosimilar resource: Biosimilars: A Guide to Regulatory and Intellectual Property Issues.

Areas of Practice
Domaines D’Expertise





Ms. Lu is experienced in all phases of patent litigation including pre-suit patent analysis, fact and expert discovery, motion practice, summary judgment, bench and jury trials, and post-trial briefing.

Representative matters include:

  • Genzyme Corp. v. Dr. Reddy’s Labs., Ltd., No. 13-1506-GMS (D. Del.) – Represented Teva Pharmaceuticals USA, Inc. in patent infringement litigation, including trial, regarding Teva’s application to market a generic version of Genzyme’s stem cell mobilizing agent, Mozobil® (plerixafor).
  • Reckitt Benckiser Pharmaceuticals Inc. v. Dr. Reddy’s Laboratories, S.A., No. 14-1451-RGA (D. Del.) – Represented Dr. Reddy’s in patent infringement litigation, including trial, concerning Dr. Reddy’s applications to market generic versions of Suboxone® (buprenorphine hydrochloride and naloxone hydrochloride) sublingual films.  After trial, the court found that Dr. Reddy’s proposed generic product did not infringe any of the asserted patents.  The case is currently on appeal.
  • Indivior Inc. v. Dr. Reddy’s Laboratories, S.A., No. 17-7111 (D. N.J.) – Representing Dr. Reddy’s in patent infringement litigation, including a hearing on motion for a preliminary injunction, concerning Dr. Reddy’s applications to market generic versions of Suboxone® (buprenorphine hydrochloride and naloxone hydrochloride) sublingual films.
  • GlaxoSmithKline v. Teva Pharmaceuticals USA, Inc., No. 14-878-LPS (D. Del.) – Represented Teva in patent litigation, including jury trial, concerning Teva’s generic version of Coreg® (carvedilol) tablets. The court granted judgment as a matter of law in favor of Teva.  The case is currently on appeal.
  • Sophos, Inc. v. RPost Holdings, Inc., No. 13-12856-DJC (D. Mass.) – Represented Sophos in declaratory judgment action regarding Sophos’s network security and email security products.  The court granted Sophos’s motion for summary judgment of invalidity on two independent grounds.  The case is currently on appeal.
  • Genentech, Inc. v. Celltrion, Inc., No. 18-cv-0574 (D. N.J.) – Represented Celltrion and Teva in patent infringement litigation under the BPCIA, including preparations for hearing on motion for a preliminary injunction, concerning Celltrion’s and Teva’s proposed biosimilar rituximab product.

Ms. Lu also commits to pro bono matters including representing unaccompanied minors through the firm’s partnership with Kids in Need of Defense (KIND).

While in law school, Ms. Lu was a student and student director in the Immigration Legal Services Clinic at Yale Law School, and an editor for the Yale Law Journal. She also worked as a summer intern at the Department of Justice Civil Rights Division, Housing and Civil Enforcement Section.

In The News









J.D., 2014
Yale Law School
A.B., 2011
Harvard College
(magna cum laude; Phi Beta Kappa; John Harvard Scholar)





U.S. District Court for the District of Massachusetts
U.S. Court of Appeals for the Federal Circuit
U.S. Supreme Court
Profile Image
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.


Search Other Lawyers
Recherche par Pratique